Molecular Imaging in Multiple Myeloma

1. Front Matter

   Pages i-v

   PDF

2. Multiple Myeloma: Clinical Aspects

   • Paola Tacchetti, Michele Cavo

   Pages 1-13

3. What Does a Clinician Need from New Imaging Procedures?

   • Elena Zamagni

   Pages 15-26

4. FDG PET in Multiple Myeloma

   • Bastien Jamet, Clément Bailly, Thomas Carlier, Anne-Victoire Michaud, Cyrille Touzeau, Philippe Moreau et al.

   Pages 27-38

5. Role of Standard Magnetic Resonance Imaging

   • Eugenio Salizzoni, Alberto Conficoni, Manuela Coe

   Pages 39-72

6. Whole Body Diffusion-Weighted Magnetic Resonance Imaging: A New Era for Whole Body Imaging in Myeloma?

   • Christina Messiou, Dow-Mu Koh

   Pages 73-85

7. CXCR4 Imaging in Multiple Myeloma

   • M. I. Morales, C. Lapa, A. K. Buck

   Pages 87-92

8. PET/CT with Standard Non-FDG Tracers in Multiple Myeloma

   • Cristina Nanni

   Pages 93-97

9. The Issue of Interpretation

   • Cristina Nanni

   Pages 99-104

10. Clinical Teaching Cases: FDG PET/CT

    • Cristina Nanni, Lucia Zanoni, Stefano Fanti

    Pages 105-136

This book provides a comprehensive overview of the importance of molecular imaging in multiple myeloma, with detailed explanation of its clinical impact. Other important features are the definition of criteria that will aid PET/CT interpretation; identification and explanation of the most frequent pitfalls; a brief overview of the advantages and limitations of DWI MR imaging, still an experimental technique in multiple myeloma; and examination of the possible role of emerging PET tracers. When appropriate, clinical cases are used to illustrate key teaching points. All physicians involved in oncological imaging should regularly reassess and update their routine practice in the evaluation of multiple myeloma patients. This is especially true now, given the recent clarification by the International Myeloma Working Group (IMWG) of the criteria for bone damage requiring therapy and the emerging data supporting the role of the newer functional imaging techniques in predicting outcome and/orevaluating response to therapy. In this challenging context, Molecular Imaging in Multiple Myeloma will be of high value for nuclear medicine physicians, radiologists, and hematologists.

• Molecular Imaging in Multiple Myeloma
• PET/CT in Multiple Myeloma
• MRI in Multiple Myeloma
• Multiparametric MRI in Multiple Myeloma
• Non FDG Radiopharmaceuticals
• FDG PET/CT in Multiple Myeloma
• Assessing Therapy Response in Multiple Myeloma
• Prognosis in Multiple Myeloma
• Interpretation Criteria in Nuclear Imaging of Multiple Myeloma
• Pitfalls in Multiple Myeloma
• DWI MR imaging in Multiple Myeloma
• oncological imaging

• Department of Metropolitan, Nuclear Medicine, Policlinico S.Orsola-Malpighi, Bologna, Italy

  Cristina Nanni, Stefano Fanti, Lucia Zanoni

Cristina Nanni is a nuclear medicine physician who works in the Nuclear Medicine Department of Sant'Orsola-Malpighi Polyclinic in Bologna, Italy. She has extensive experience in PET in oncology, multimodality oncological imaging, and non-FDG imaging in oncology and is in charge of multiple myeloma PET imaging at the hospital.  Dr. Nanni is currently participating in an extensive project on standardization of PET imaging for multiple myeloma. She is the author of more than 200 full articles in peer-reviewed international journals.

Stefano Fanti is full professor in Nuclear Medicine at the University of Bologna. He is head of the Nuclear Medicine Division and the PET Unit at Sant'Orsola-Malpighi Polyclinic, and Director of the Specialty School of Nuclear Medicine at the University of Bologna. Dr. Fanti has extensive experience in oncological PET (especially non-FDG tracers). He has been an invited lecturer at more than 250 national and international meetings and isthe author of over 350 full articles in peer-reviewed international journals.

Lucia Zanoni is a nuclear medicine physician who works in the Nuclear Medicine Department of Sant'Orsola-Malpighi Polyclinic in Bologna. She has extensive experience of the use of PET in oncology and of multimodality oncological imaging. 

Policies and ethics